Decibel Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Decibel Therapeutics

14/03/2023 13:06

* Decibel Therapeutics Inc  DBTX.OQ   DBTX.O  is expected
to show
a rise in quarterly revenue when it reports  results on March 16
(estimated). 
    * The Boston Massachusetts-based  company is expected to
report
revenue of $7.5 million, according to the mean estimate from 4
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Decibel
Therapeutics Inc
is for a loss of 40 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Decibel
Therapeutics Inc is $13​, above​ its last closing price
of $4.07. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.70       -0.69      -0.64     Beat    6.7
 Jun. 30 2022  -0.57       -0.57      -0.68     Missed  -19.4
 Mar. 31 2022  -0.56       -0.56      -0.56     Met     -0.8​
 Dec. 31 2021  -0.23       -0.47      -0.49     Missed  -3.2
 ​​Sep.        -0.44       -0.43      -0.59     Missed  -36.6
 30 2021                                                
 Jun. 30 2021  -0.41       -0.37      -0.47     Missed  -26.4​
 Mar. 31 2021  -0.54       -0.54      -1.09     Missed  -102.2
 This summary was machine generated March 14 at 13:06 GMT.  All
figures in US dollars  unless otherwise stated